AVR · Anteris Technologies Global Corp.

Current Thesis

Anteris Technologies' PARADIGM-led recovery thesis has failed its published $9.00 weekly-close condition: the market closed at $8.16 on 2026-09-18. The underlying clinical story remains progress toward commercialization of the DurAVR transcatheter aortic valve, supported by the company's 2026-08-11 report of active PARADIGM recruitment in the United States, Denmark and the Netherlands. Recruitment establishes trial execution; it does not establish comparative clinical success. Q2 company release

For the recovery leg described in the previous coverage, the narrative is dead — the 2026-09-18 weekly close breached the published threshold after the September conference window elapsed. That is an interpretation of the price structure, not a finding that DurAVR has failed clinically. The company's press-release archive, checked on 2026-09-20, still ends with its 2026-08-31 conference announcement; it supplies no subsequent operational release establishing a replacement thesis. Company announcements

Bullish and bearish views on Anteris Technologies Global Corp.

The model's bull view on Anteris Technologies Global Corp. (AVR), in brief: Recruitment has crossed national borders. The bear view: The published recovery condition failed. Both cases follow in full.

Bull Case

• Recruitment has crossed national borders. The 2026-08-11 company update reported active recruitment in the United States, Denmark and the Netherlands, alongside regulatory clearance in Canada and France. These are observable execution milestones; clearance and active enrollment remain distinct. Q2 company release
• Reimbursement supports eligible trial procedures. The 2026-08-11 update confirmed Medicare reimbursement eligibility and reported that the first United States patients were treated in May 2026. This supports the trial's operating framework without resolving the pivotal clinical question. Q2 company release

Bear Case

• The published recovery condition failed. The supplied adjusted market series records an $8.16 close on 2026-09-18, below the $9.00 weekly threshold published in the 2026-09-06 coverage. A lower replacement threshold would erase that failure rather than explain it.
• Trial execution consumes substantial cash. For the quarter ended 2026-06-30, Anteris reported $20.8 million of operating cash outflow and $23.4 million of research and development expense, attributing spending to clinical, regulatory and manufacturing work. Those amounts do not establish a cash runway without a current cash balance. Q2 company release, 2026-08-11
• Financing capacity permits further dilution. The 2026-05-22 announcement described an at-the-market common-stock program of up to $250 million. The supplied evidence does not establish subsequent proceeds or utilization, so the facility supports a dilution risk rather than a claim that issuance caused September's weakness. The prospectus and sales agreement appear in the exchange archive on 2026-05-25. ASX announcement register

Setup & Price Structure

Measured on 2026-09-18, the adjusted close was $8.16, the three-month price change was -14.9%, and the shares stood 22.8% below the reported $10.57 trailing-year high. The 14-period relative strength index (RSI) was 39.5. These observations establish weakness; they do not establish a durable floor.

The $9.00 level retains its meaning as the previously published recovery threshold. The September close has already invalidated that structure, and the supplied series does not establish another support shelf below it.

The 2026-08-31 announcement clustered investor appearances on 2026-09-09, 2026-09-10 and 2026-09-14. That is evidence of concentrated company marketing, not measured retail crowding or expanding ownership. No current short-interest series, fund-flow series or moving-average value is available here to support a stronger positioning claim. Company conference announcement index

Catalyst Calendar (next 30 days)

For 2026-09-20 through 2026-10-20, no company-confirmed clinical readout, earnings release or investor event was identified in the reviewed announcements. The 2026-09-30 quarter-end is an accounting boundary, not a confirmed disclosure date. The September conference dates have elapsed and do not qualify as upcoming catalysts. Company announcements

Since the previous coverage, the ASX register lists a chief financial officer appointment on 2026-09-07 and officer compensation arrangements on 2026-09-18. Those dated filing titles establish corporate updates; they do not establish a new enrollment count or clinical outcome. ASX announcement register

What Would Change Our Mind

Loss of the published recovery threshold settles the existing price thesis: a weekly close below $9.00 is its invalidation condition, already satisfied by the $8.16 close on 2026-09-18. The historical outcome remains a failure even if the shares subsequently recover.

A replacement recovery case would require both a weekly close above $9.00 and a dated company disclosure demonstrating enrollment progress beyond the 2026-08-11 update. Its price condition would fail on a subsequent weekly close below $9.00; an announced suspension of PARADIGM enrollment would independently break its clinical premise. Neither replacement condition is established by the evidence reviewed through 2026-09-20.

Correlation Notes

This remains a single-name clinical-device setup. The 2026-08-11 company update ties operating expenditure to PARADIGM execution, while the supplied 2026-09-18 observations contain no matched peer or index return series. They cannot establish a statistical correlation or support attributing the decline to a sector move. The relevant research theme is cardiovascular devices, consistent with the company's DurAVR trial, rather than oncology or diagnostics. Q2 company release